Abstract:Objective To investigate the effects of fenofibrate (FF), a peroxisome proliferator- activator receptor α (PPAR-α) activator on the cardiac injury caused by myocardial ischemia and mechanism thereof. Methods Forty-eight male SD rats were randomly divided into 3 equal groups: isoproterenol (ISO) group and control group both undergoing gastric lavage of normal saline (NS) 20 ml/kg once a day for 7d, and FF pretreatment group, undergoing gastric lavage of FF solved in NS 20 ml/kg once a day for 7d.One hour after the last lavage the FF and ISO groups underwent intraperitoneal injection of ISO 5 mg/kg, and the control group underwent intrapeitoneal injection of NS. 24 h later blood samples was obtained by picking out the eyeball to isolate serum. And then the hearts were taken out for measurement of heart weight (HW), pathology of the myocardium, and calculation of the HW/body weight (BW)% and infarction size (IS)/ventricular weight (VW)%. Nitrate reductase method and double antibody sandwich ELISA were used to detect the serum nitrogen oxide (NO) and tumor necrosis factor ( TNF)-α. Sodium dodecyl sulfate polyacrylamide gel electrophoresis was used to examine the PPARα protein expression in the myocardium. Results The HW/BW of the ISO group was (6.71±0.55) mg/g, significantly higher than that of the control group [(4.05±0.37) mg/g, P<0.01], and the HW/BW of the FF group was (5.28±0.49) mg/g, significantly lower than that of the ISO group (P <0.05) and still significantly higher than that of the control group (P <0.05). The IS/VW% of the ISO group was (0.75±0.09)%, significantly higher than that of the control group [(0.07±0.02)%, P <0.01]; and the IS/VW% of the FF group was (0.31±0.08)%, significantly lower than that of the ISO group (P <0.01) and still significantly higher than that of the control group (P <0.01). The serum NO level of the ISO group was (20.79±5.95) μmol/L, significantly lower than that of the control group [(49.65±6.97)μmol/L, P <0.01], and the serum NO level of the FF group was (80.45±11.61) μmol/L, significantly higher than those of the control and ISO groups (both P <0.01). The serum TNF-α level of the ISO group was (275.41±27.61)%, significantly higher than that of the control group [(20.01±3.29)%, P <0.01]; and the serum TNF-α level of the FF group was (149.07±22.39)%, significantly lower than that of the ISO group (P <0.01), but still significantly higher than that of the control group (P <0.01). The PPARα protein expression level of the ISO group was significantly lower than that of the control group (P <0.05), and the PPARα protein expression level of the FF group was significantly higher than those of the ISO and control groups (both P <0.05). Conclusion FF reduces the cardiac infarction area and protects the heart from ischemic injury via activating PPARα.

Fenofibrate Increases Heme Oxygenase 1 Expression and Astrocyte Proliferation While Limits Neuronal Injury During Intracerebral Hemorrhage

PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Neuroprotective Effects of Prostaglandin A(1) in Rat Models of Permanent Focal Cerebral Ischemia Are Associated with Nuclear Factor-Kappa B Inhibition and Peroxisome Proliferator-Activated Receptor-Gamma Up-Regulation

Fenofibrate Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice: Involvements of Apoptosis, Autophagy, and PPAR-α Activation

Downregulating Hypoxia-Inducible Factor-1Α Expression with Perfluorooctyl-Bromide Nanoparticles Reduces Early Brain Injury Following Experimental Subarachnoid Hemorrhage in Rats.

Hypoxia Inducible Factor-1α Attenuates Ischemic Brain Damage by Modulating Inflammatory Response and Glial Activity.

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Effects of fenofibrate on acute myocardial ischemic damage induced by isoproterenol: experiment with rats

Fenofibrate inhibits hypoxia‐inducible factor‐1 alpha and carbonic anhydrase expression through activation of AMP‐activated protein kinase/ HO ‐1/Sirt1 pathway in glioblastoma cells

Heme Oxygenase 1 Plays Role of Neuron-Protection by Regulating Nrf2-ARE Signaling Post Intracerebral Hemorrhage.

The Protective Effect of Fenofibrate on Acute Focal Cerebral Ischemia Reperfusion Injury in Mice

Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

PGE1 triggers Nrf2/HO-1 signal pathway to resist hemin-induced toxicity in mouse cortical neurons

Activation of PPAR Alpha by Fenofibrate Inhibits Apoptosis in Vascular Adventitial Fibroblasts Partly Through SIRT1-mediated Deacetylation of FoxO1.

PPARalpha Agonist Fenofibrate Protects the Kidney from Hypertensive Injury in Spontaneously Hypertensive Rats Via Inhibition of Oxidative Stress and MAPK Activity.

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

In vivo PPAR|[alpha]| activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting tetrahydrobiopterin in mineralocorticoid hypertension

Fenofibrate Decreases Asymmetric Dimethylarginine Level in Cultured Endothelial Cells by Inhibiting NF-κB Activity

Fenofibrate Ameliorates Cardiac Hypertrophy by Activation of Peroxisome Proliferator-Activated Receptor-Α Partly Via Preventing P65-Nfκb Binding to NFATc4.